Text Version
RSS Feeds
Newsletter
Home Forum Photos Features Newsletter Archive Employment
About US Help Site Map
SEARCH   About US FAQ Site Map Site News
  SERVICES
  -Text Version
  -RSS Feeds
  -Newsletter
  -News Archive
  -Give us feedback
  -Voices of Readers
  -Online community
  -China Biz info
  What's new
 -
 -
Roche to acquire Genentech for $46.8 bln
+ -
15:32, March 13, 2009

Click the "PLAY" button and listen. Do you like the online audio service here?
Good, I like it
Just so so
I don't like it
No interest
 Comment  Tell A Friend
 Print Format  Save Article
Genentech, a biotechnology industry pioneer based in South San Francisco, on Thursday agreed to be acquired by Swiss pharmaceutical giant Roche for 46.8 billion U.S. dollars.

In a joint statement, the two companies said they had reached agreement to allow Roche to buy the 44 percent of Genentech shares it doesn't already own for 95 dollars per share in cash.

"We have had a highly successful partnership with Roche for more than 18 years, and we intend to pursue our shared goal of discovering medications for serious and life-threatening conditions," Arthur Levinson, chief executive officer of Genentech, said in the statement.

"We look forward to working with our partners at Roche to ensure a smooth transition once the transaction is complete and to continue our mission of serving patients," he added.

The combined company will be the seventh largest U.S. pharmaceuticals company in terms of market share, generating about17 billion dollars in annual revenues with around 17,500 employees in the U.S. pharmaceuticals business alone.

Research and early development will operate as an independent center within Roche from its existing campus in South San Francisco, the two companies said, promising that Genentech's "unique culture" will be maintained.

Roche's Pharma commercial operations in the United States will also be moved from New Jersey to South San Francisco.

The combined company's U.S. commercial operations in pharmaceuticals will operate under the Genentech name, leveraging the strong brand value of Genentech in the U.S. market.

Founded in 1976, Genentech has rolled out many "firsts" in drug development including the first antibody treatment for cancer.

Genentech played a leading role in the development of the nascent biotech industry of the 1970s, which is comparable to Apple's place in the rise of the personal computer, the San Francisco Chronicle newspaper said in a report.

Source: Xinhua



  Your Message:   Most Commented:
British boy becomes father at 13
Looted Chinese relics sold for 14 million euros each
Full Text of Human Rights Record of United States in 2008
China hits back with report on U.S. human rights record
Spanish Tibetologist: "What I see and hear in Tibet differs from Dalai Lama's propaganda"

|About Peopledaily.com.cn | Advertise on site | Contact us | Site map | Job offer|
Copyright by People's Daily Online, All Rights Reserved

http://english.people.com.cn/90001/90778/90858/90864/6613804.pdf